Alexander M. Gold
Known title: DirectorCIK: 0002026429
Associated companies
Transaction History
| MLYS | ▲ Buy | Grant | 6,200 | $0 | 2/19/2026 | View on chart |
| MLYS | ▲ Buy | Option Exercise | 2,742 | $28K | 11/13/2025 | View on chart |
| MLYS | ▲ Buy | Option Exercise | 10,000 | $127K | 11/13/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 12,742 | $593K | 11/13/2025 | View on chart |
| MLYS | ▲ Buy | Option Exercise | 6,933 | $71K | 11/12/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 5,000 | $233K | 11/12/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 1,933 | $91K | 11/12/2025 | View on chart |
| MLYS | ▲ Buy | Option Exercise | 15,000 | $153K | 11/11/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 10,000 | $424K | 11/11/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 5,000 | $235K | 11/11/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Mineralys Presents Phase 3 Data, Receives Mixed Analyst Views
Mineralys Therapeutics presented new data from its pivotal Phase 3 Launch-HTN study at the American Heart Association Hypertension Scientific Sessions 2026. Following this update, UBS initiated coverage with a Neutral rating and a $29 price target, while HC Wainwright reiterated a Buy rating with a $56 target. The stock is currently trading near its support level, reflecting the divided analyst opinions on the company's outlook.
Mineralys Presents Phase 3 Data, Receives Mixed Analyst Views. Mineralys Therapeutics presented new data from its pivotal Phase 3 Launch-HTN study at the American Heart Association Hypertension Scientific Sessions 2026. Following this update, UBS initiated coverage with a Neutral rating and a $29 price target, while HC Wainwright reiterated a Buy rating with a $56 target. The stock is currently trading near its support level, reflecting the divided analyst opinions on the company's outlook.